RUBY - Rubius Therapeutics - Stock Forecast

Coverage Performance Price Targets & Ratings Chart Insider Trading

RUBY is currently covered by 5 analysts with an average price target of $2.44. This is a potential upside of $2.38 (3966.67%) from yesterday's end of day stock price of $0.06.

Rubius Therapeutics's activity chart (see below) currently has 19 price targets and 28 ratings on display. The stock rating distribution of RUBY is 72.73% HOLD and 27.27% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 49.44% with an average time for these price targets to be met of 127.5 days.

Highest price target for RUBY is $3, Lowest price target is $1, average price target is $2.44.

Most recent stock forecast was given by MICHAEL SCHMIDT from GUGGENHEIM on 13-Sep-2022. First documented stock forecast 13-Aug-2018.

Best performing analysts who are covering RUBY - Rubius Therapeutics:

Michael Schmidt Jonathan Chang Jessica Fye Matthew Harrison Jeffrey Hung Andrew Fein

Currently out of the existing stock ratings of RUBY, 8 are a HOLD (72.73%), 3 are a BUY (27.27%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

5

1 years 6 months 16 days ago

2/4 (50%)

$2.59 (107.47%)

488

Hold

1.5

$1.44 (2400.00%)

2

1 years 6 months 20 days ago

0/4 (0%)

$0.38 (33.93%)

Hold

1

$0.94 (1566.67%)

1 years 7 months 20 days ago

4/5 (80%)

$0.2 (25.00%)

245

Hold

1 years 10 months 18 days ago

2/3 (66.67%)

$0.49 (5.15%)

5

Buy

1 years 10 months 18 days ago

0/3 (0%)

$9.71 (32.06%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RUBY (Rubius Therapeutics) average time for price targets to be met?

On average it took 127.5 days on average for the stock forecasts to be realized with a an average price target met ratio 49.44

Which analyst has the current highest performing score on RUBY (Rubius Therapeutics) with a proven track record?

MICHAEL SCHMIDT

Which analyst has the current lower performing score on RUBY (Rubius Therapeutics) with a proven track record?

ANDREW FEIN

Which analyst has the most public recommendations on RUBY (Rubius Therapeutics)?

Michael Schmidt works at GUGGENHEIM and has 3 price targets and 2 ratings on RUBY

Which analyst is the currently most bullish on RUBY (Rubius Therapeutics)?

Jessica Fye with highest potential upside - $5.98

Which analyst is the currently most reserved on RUBY (Rubius Therapeutics)?

Michael Schmidt with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?